adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine clinical trials

A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.

This study looks at a new flu jab for people aged 50 and over. It compares how well this new high-dose jab works and its safety, against two other existing flu jabs. The aim is to find out if the new jab offers better protection.